BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
BCRX on Nasdaq
Shares outstanding
210,587,372
Price per share
$6.67
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
208,529,341
Total reported value
$1,625,979,645
% of total 13F portfolios
0%
Share change
+12,861,585
Value change
+$103,910,012
Number of holders
271
Price from insider filings
$6.67
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.4% $143,714,288 17,483,490 BlackRock, Inc. 31 Mar 2025
RA CAPITAL MANAGEMENT, L.P. 7.3% $116,143,592 15,302,186 RA Capital Management, L.P. 04 Nov 2025
Flynn James E 6.8% +17% $109,278,420 +$16,550,640 14,341,000 +18% Deerfield Mgmt, L.P. 31 Dec 2025
STATE STREET CORP 5.3% $84,377,868 11,073,211 STATE STREET CORPORATION 31 Dec 2025
Avoro Capital Advisors LLC 4.2% $71,514,000 8,700,000 Avoro Capital Advisors LLC 31 Mar 2025

As of 31 Dec 2025, 271 institutional investors reported holding 208,529,341 shares of BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX). This represents 99% of the company’s total 210,587,372 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX) together control 75% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 11% 22,273,375 +2.2% 0% $173,732,325
BlackRock, Inc. 10% 21,137,791 -0.51% 0% $164,874,767
RA CAPITAL MANAGEMENT, L.P. 7.5% 15,827,186 1.3% $123,452,051
DEERFIELD MANAGEMENT COMPANY, L.P. 6.8% 14,341,000 +18% 1.4% $111,859,800
STATE STREET CORP 5.3% 11,073,211 +13% 0% $86,371,046
Kynam Capital Management, LP 4.4% 9,366,526 -0.25% 4.8% $73,058,903
JANUS HENDERSON GROUP PLC 3.5% 7,404,386 +7807% 0.03% $57,791,233
UBS Group AG 2.5% 5,263,914 -12% 0.01% $41,058,529
GEODE CAPITAL MANAGEMENT, LLC 2.4% 5,053,786 +0.03% 0% $39,426,800
TWO SIGMA INVESTMENTS, LP 2.1% 4,515,317 +2.2% 0.05% $35,219,473
TWO SIGMA ADVISERS, LP 1.9% 4,089,112 -3.6% 0.06% $31,895,074
Nuveen, LLC 1.7% 3,612,366 -0.15% 0.01% $28,176,454
GOLDMAN SACHS GROUP INC 1.5% 3,212,785 +18% 0% $25,059,723
PERCEPTIVE ADVISORS LLC 1.5% 3,162,529 0.45% $24,667,726
GW&K Investment Management, LLC 1.5% 3,160,924 +44% 0.21% $24,655,000
Eversept Partners, LP 1.4% 2,992,895 +118% 1.3% $23,344,581
BAKER BROS. ADVISORS LP 1.3% 2,822,727 0.13% $22,017,271
BNP PARIBAS FINANCIAL MARKETS 1.2% 2,542,714 0% 0.01% $19,833,169
Fisher Asset Management, LLC 1.2% 2,467,567 -6.3% 0.01% $19,247,022
Vestal Point Capital, LP 1.1% 2,250,000 0.64% $17,550,000
Qube Research & Technologies Ltd 1% 2,164,162 -10% 0.02% $16,880,464
Elmind Capital, LP 1% 2,150,000 0% 4.9% $16,770,000
RENAISSANCE TECHNOLOGIES LLC 1% 2,128,821 -0.55% 0.03% $16,604,804
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.95% 2,004,939 +0.53% 0% $15,638,524
RICE HALL JAMES & ASSOCIATES, LLC 0.9% 1,904,146 +1.3% 0.82% $14,852,339

Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 208,529,341 $1,625,979,645 +$103,910,012 $7.80 271
2025 Q3 194,130,983 $1,473,337,203 -$36,097,402 $7.59 283
2025 Q2 197,129,798 $1,766,723,682 +$203,493,373 $8.96 292
2025 Q1 174,435,511 $1,308,746,834 +$63,398,447 $7.50 273
2024 Q4 167,662,220 $1,261,171,584 -$40,361,715 $7.52 256
2024 Q3 173,102,982 $1,315,577,234 -$13,496,556 $7.60 255
2024 Q2 174,343,886 $1,077,260,403 -$26,171,848 $6.18 238
2024 Q1 179,854,267 $913,665,406 +$14,530,963 $5.08 235
2023 Q4 176,879,832 $1,059,530,995 -$13,874,803 $5.99 234
2023 Q3 175,748,697 $1,244,274,073 +$20,781,164 $7.08 229
2023 Q2 174,092,743 $1,225,943,210 +$15,794,543 $7.04 233
2023 Q1 170,682,621 $1,423,483,184 +$98,954,044 $8.34 237
2022 Q4 157,670,070 $1,809,819,957 +$89,114,288 $11.48 225
2022 Q3 149,200,472 $1,879,908,994 -$39,491,355 $12.60 218
2022 Q2 151,882,406 $1,606,941,793 +$202,016,904 $10.58 207
2022 Q1 127,644,333 $2,074,127,946 +$162,394,498 $16.26 219
2021 Q4 118,034,837 $1,624,605,826 +$189,498,647 $13.85 197
2021 Q3 103,285,294 $1,484,281,647 -$23,674,937 $14.37 191
2021 Q2 104,615,646 $1,653,902,810 +$25,597,252 $15.81 190
2021 Q1 104,536,942 $1,063,154,138 -$141,911,795 $10.17 183
2020 Q4 120,536,116 $897,922,105 -$43,570,187 $7.45 172
2020 Q3 127,504,811 $438,191,012 -$23,494,376 $3.44 150
2020 Q2 133,168,915 $634,861,180 +$96,615,986 $4.76 160
2020 Q1 122,545,605 $245,076,906 -$37,929,778 $2.00 127
2019 Q4 137,257,236 $473,298,973 +$126,158,746 $3.45 131
2019 Q3 98,732,839 $282,887,178 -$6,967,337 $2.86 110
2019 Q2 100,189,285 $379,651,222 -$87,862,478 $3.79 112
2019 Q1 101,459,192 $825,845,210 +$1,493,806 $8.14 129
2018 Q4 101,241,798 $817,039,643 +$8,890,495 $8.07 118
2018 Q3 100,143,382 $764,063,804 +$73,654,467 $7.63 110
2018 Q2 87,486,065 $501,300,833 -$8,812,924 $5.73 98
2018 Q1 89,084,172 $424,940,474 -$6,631,982 $4.77 98
2017 Q4 90,315,627 $443,489,038 +$30,241,042 $4.91 111
2017 Q3 83,706,610 $438,584,580 +$76,310,817 $5.24 118
2017 Q2 69,068,637 $384,022,057 +$3,627,924 $5.56 112
2017 Q1 67,625,892 $568,043,111 +$140,009,973 $8.40 114
2016 Q4 58,390,925 $369,592,679 +$11,848,602 $6.33 107
2016 Q3 56,560,503 $249,434,126 +$23,437,473 $4.41 98
2016 Q2 51,754,204 $146,980,142 -$10,557,522 $2.84 91
2016 Q1 55,499,247 $157,041,490 -$57,851,659 $2.83 103
2015 Q4 63,010,560 $650,239,667 -$21,193,454 $10.32 116
2015 Q3 64,961,257 $740,441,332 +$18,203,435 $11.40 123
2015 Q2 62,979,534 $940,208,410 -$26,293,353 $14.93 121
2015 Q1 64,945,642 $586,470,031 +$36,664,370 $9.03 96
2014 Q4 60,839,929 $739,630,154 +$22,530,982 $12.16 90
2014 Q3 56,671,419 $554,271,573 +$30,624,768 $9.78 101
2014 Q2 53,076,615 $676,805,598 +$130,669,664 $12.75 100
2014 Q1 43,477,699 $460,383,679 +$93,247,685 $10.58 86